DEF 14A

Company

Inhibikase Therapeutics, Inc.

Filed

May 5, 2023

Period of Report

June 23, 2023

Accession Number

0000950170-23-018354

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →